Please login to the form below

Not currently logged in
Email:
Password:

licensing agreements

This page shows the latest licensing agreements news and features for those working in and with pharma, biotech and healthcare.

‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

Licensing. Also of relevance to the pharmaceutical sector is the impact of Brexit on IP licensing. ... Future licence agreements should be drafted to specifically address the effect of Brexit on any relevant provisions.

Latest news

  • GSK unveils access plan for low-income countries GSK unveils access plan for low-income countries

    The MPP was set up in 2010 and focuses on voluntary licensing agreements with companies serving in low-income countries and LMICs. ... month. Another firm active in this area is Gilead Sciences, which signed licensing deals with Indian generics companies

  • AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

    As well as resisting the $100bn overture from Pfizer earlier this year, Soriot has instigated a range of acquisitions and licence agreements. ... These include licensing the WEE1 inhibitor MK-1775 from Merck &Co, the $500m buyout of biotech Amplimmune

  • AZ buys into ADC sector with $440m Spirogen deal AZ buys into ADC sector with $440m Spirogen deal

    AstraZeneca has made a push into the market for antibody-drug conjugates (ADCs) via the acquisition of Spirogen and a licensing deal with ADC Therapeutics. ... The agreements will allow it to "accelerate ADCs into the clinic", according to Dr Bahija

  • Gilead works with Indian generic firms to improve HIV drug access Gilead works with Indian generic firms to improve HIV drug access

    A total of thirteen Indian generic companies now have licensed Gilead HIV medicines through non-exclusive generic licensing agreements established with generic manufacturers.

  • The development of stem cell therapies The development of stem cell therapies

    The company is preparing to develop the product in other regions through licensing agreements with pharmaceutical companies in North America, Europe, Asia and the Middle East.

More from news
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    We will be very active in building partnerships and licensing agreements.

  • A new route to market A new route to market

    Licensing agreements. A common model for many small to medium sized biotech companies taking a first step in exporting is to license a product or technology to a local market partner - ... Licensing agreements are rarely straightforward, and a level of

  • Pharma deals during October 2013 Pharma deals during October 2013

    Pharma deals during October 2013. Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month. ... Pre-existing out-licensing agreements, which include milestones and royalties, remain in effect and these have been transferred

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    Others, such as Roche, are partnering with local manufacturers under out-licensing agreements. ... The government has issued high-profile proposals around compulsory licensing and price-capping.

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    Healthy pipeline. Across its various therapy areas, the company expects to have ten products, developed in-house or through in-licensing agreements, in launch or early growth phase over the next ... This enables us to look across the whole landscape, not

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics